Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy-Reference-Cited by-同舟云学术

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy

Published:2023-03 Issue: Volume:Volume 19 Page:301-312
ISSN:1178-203X
Container-title:Therapeutics and Clinical Risk Management
language:en
Short-container-title:TCRM

Author:

Colombo Giorgio Lorenzo^ORCID,Valentino Maria Chiara^ORCID,Fabi Alessandra,Dieci Maria Vittoria,Caruggi Mauro,Bruno Giacomo Matteo^ORCID,Lombardi Gloria,Di Matteo Sergio

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Safety Research,General Medicine

Reference36 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

2. AIOM-AIRTUM. I numeri del cancro in Italia. Disponibile all’indirizzo; 2019. Available from: https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-web.pdf. Accessed March 15, 2023.

3. Molecular portraits of human breast tumours

4. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer

5. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE;EXCLI J;2024

2. CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment;Medicine;2023-10-06

3. Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy;Breast Cancer Management;2023-06-01